Meeting
2024 ASCO Annual Meeting
REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).
Authors
Isabelle Laure Ray-Coquard
Department of Medical Oncology, Centre Léon Bérard, and GINECO, Lyon, France
Isabelle Laure Ray-Coquard , Debra L. Richardson , Kosei Hasegawa , Connor Mailley , Sandra Re , Madan Gopal Kundu , Jie Lin , Kathleen N. Moore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT06161025
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS5625)
DOI
10.1200/JCO.2024.42.16_suppl.TPS5625
Abstract #
TPS5625
Poster Bd #
494a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
First Author: Ursula A. Matulonis
Poster
2022 ASCO Annual Meeting
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
First Author: Lingying Wu
Poster
2022 ASCO Annual Meeting
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Thomas J. Herzog
Poster
2021 ASCO Annual Meeting
Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT‑cx12/GOG 3057, trial in progress).
First Author: Ignace Vergote